An advisory panel of the US Centers for Disease Control and Prevention (CDC) on Thursday decided not to recommend boosters for younger adults, including healthcare workers, who live or work in institutions with high risk of contracting COVID-19, Reuters news agency reported on Friday.
The panel has only recommended a booster shot of the Pfizer (NYSE:PFE)/BioNTech (Nasdaq:BNTX) COVID-19 vaccine for Americans aged 65 and older and some adults with underlying medical conditions that put them at risk of severe disease.
For now, the panel has rejected additional doses for groups including healthcare workers, teachers and residents of homeless shelters and prisons, in part because of the difficulty of implementing such a proposal.
In addition to older Americans, the committee also recommended the booster shots for all adults over 50 with underlying conditions, as well as some 18- to 49-year-olds with those conditions, based on their individual risk profile. Those conditions include cancer, diabetes, certain heart conditions and chronic kidney disease and lung disorders.
The recommendations only cover people who received their second Pfizer/BioNTech shot at least six months earlier. This group is currently about 26 million people, including 13 million aged 65 or older, the CDC said.
Bavarian Nordic sells US Priority Review Voucher for USD160m
Bavarian Nordic sells US Priority Review Voucher for USD160m
ArcticZymes Technologies launches GMP-grade nuclease for viral vector manufacturing
Merck launches Phase 3 trial for dengue vaccine candidate V181
BioNet and Bio Farma sign MoU on TdaP vaccine
Dx&Vx accelerates universal COVID-19 vaccine development
Moderna withdraws application for flu-COVID combination vaccine pending additional efficacy data
CTP delivers 18,000 sqm Serbian facility for SCHOTT Pharma to support global expansion
LakeShore Biopharma launches novel packaging solution for YSJA rabies vaccine (Vero cell)
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment
Orexo reports positive results for powder-based intranasal vaccine using AmorphOX technology
GC Biopharma's BARYTHRAX receives Korean regulatory approval